Contributions
Abstract: PB2199
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common haematological malignancy among adults in Hungary. Renal impairment is frequent in MM patients and has fundamental impact on overall survival (OS).
Aims
Our research question was how long the waiting time of patients is from the detection of renal impairment (GFR <40 mL/min) until the start of induction therapy and how this waiting time influences OS. We also studied if reversibility/irreversibility of renal failure has an impact on OS.
Methods
We analyzed the medical history of 212 MM patients at Semmelweis University 3rd Department of Internal Medicine, Budapest, Hungary from 2007 to 2017. We studied if renal impairment (GFR <40 mL/min) was reversible (GFR >40 mL/min) or irreversible, as well as how long the patients waited from the diagnosis of renal disease until the first induction therapy for MM. We also compared ISS and FISH data and determined how all these factors influence the OS.
Results
One-third of the patients (74/212) had renal impairment at diagnosis, and in half of these cases (36/74) the renal function was reversible. Before 2012 the renal function was not reparable in 80% of patients, however after 2012 the ratio decreased to 53%, most probably due to the introduction of new generation drugs. OS was significantly lower in patients with irreversible renal failure compared to those without renal impairment (15 vs. 55 months, p=0.013), however we did not find similar significant difference in patients whose renal impairment was reversible (55 vs. 47 months, p=0.32). Importantly, the waiting time of those whose renal failure became irreversible was significantly longer compared to reversibly affected patients (7 weeks vs. 2.5 weeks, p<0.0001).
Conclusion
Our results point out the importance of speed in the diagnosis of MM. Any delay in the diagnosis and start of the induction therapy worsens the outcome of patients with MM and renal failure. Despite the positive tendency that we detected in the last few years we still have to improve the interdisciplinary cooperation in order to diagnose and treat MM patients as soon as possible.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Diagnosis, Multiple Myeloma, Renal failure, Renal impairment
Abstract: PB2199
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common haematological malignancy among adults in Hungary. Renal impairment is frequent in MM patients and has fundamental impact on overall survival (OS).
Aims
Our research question was how long the waiting time of patients is from the detection of renal impairment (GFR <40 mL/min) until the start of induction therapy and how this waiting time influences OS. We also studied if reversibility/irreversibility of renal failure has an impact on OS.
Methods
We analyzed the medical history of 212 MM patients at Semmelweis University 3rd Department of Internal Medicine, Budapest, Hungary from 2007 to 2017. We studied if renal impairment (GFR <40 mL/min) was reversible (GFR >40 mL/min) or irreversible, as well as how long the patients waited from the diagnosis of renal disease until the first induction therapy for MM. We also compared ISS and FISH data and determined how all these factors influence the OS.
Results
One-third of the patients (74/212) had renal impairment at diagnosis, and in half of these cases (36/74) the renal function was reversible. Before 2012 the renal function was not reparable in 80% of patients, however after 2012 the ratio decreased to 53%, most probably due to the introduction of new generation drugs. OS was significantly lower in patients with irreversible renal failure compared to those without renal impairment (15 vs. 55 months, p=0.013), however we did not find similar significant difference in patients whose renal impairment was reversible (55 vs. 47 months, p=0.32). Importantly, the waiting time of those whose renal failure became irreversible was significantly longer compared to reversibly affected patients (7 weeks vs. 2.5 weeks, p<0.0001).
Conclusion
Our results point out the importance of speed in the diagnosis of MM. Any delay in the diagnosis and start of the induction therapy worsens the outcome of patients with MM and renal failure. Despite the positive tendency that we detected in the last few years we still have to improve the interdisciplinary cooperation in order to diagnose and treat MM patients as soon as possible.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Diagnosis, Multiple Myeloma, Renal failure, Renal impairment